Here we report on the molecular mechanism responsible for the endocytotic process by analyzing the agonist-dependent phosphorylation of wild-type and mutant receptors expressed in human embryonic kidney cells. Wild-type SSTR3 is phosphorylated in response to agonist treatment. Phosphorylation is markedly reduced in a S341A/ S346A/S351A triple mutant and is also reduced, but to a lesser extent, in the T357A point mutant. Internalization of the wild-type receptor is preceded by a functional desensitization of the receptor; in contrast, the triple serine mutant does not desensitize after treatment with agonists as assayed by its ability to inhibit forskolinstimulated adenylate cyclase activity. After internalization via a clathrin-coated vesicle mediated endocytotic pathway, SSTR3 efficiently recycles to the cell surface, suggesting that agonist mediated endocytosis is necessary for the functional resensitization of a phosphorylated and desensitized receptor.
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to their agonists frequently causes a diminution of the initial response. This phenomenon has been termed desensitization, and it is often associated with phosphorylation of the receptor protein followed by binding of the regulatory protein ␤-arrestin (1, 2). The receptor is then internalized into an intracellular compartment where it is inaccessible to hydrophilic ligands.
␤-Arrestin has been proposed to function as an adaptor between phosphorylated receptors and clathrin cages, thus directing receptors to the endocytotic pathway (3, 4) . In the acidified environment of endosomes, the ligand is removed and the receptor is dephosphorylated and recycled to the cell surface (5, 6) .
In the case of receptors for the neuropeptide somatostatin (SST), the processes of desensitization and internalization are of considerable clinical importance as stable peptide analogs of somatostatin are used for the long term treatment of hypersecretory neuroendocrine tumors of the pituitary and pancreas (7) . These analogs not only inhibit hormone secretion, but also have an antiproliferative effect on tumor cells (8) . They are also used for the preoperative localization of tumors by SSTR scintigraphy (9), a process which presumably relies on the internalization of the radioactive ligand by its target cells.
The fact that somatostatin receptors and their ligands are internalized was originally disputed (10), but recently it was shown that several SSTR-expressing tumor cells do internalize radioactive SST analogs (11) . We have recently shown that in human embryonic kidney cells expressing individual rat SSTR subtypes (rSSTR1-5), SSTR1-3 are rapidly internalized in the presence of either of the two naturally occurring agonists, SST14 and SST28. SSTR5 is internalized only in the presence of SST28, whereas SSTR4 is not internalized by either agonist (12, 13) . Studies on the internalization of human and mouse SSTRs confirmed that internalization is subtype-selective, although some species-specific differences were reported (14, 15) . The analysis of chimeras of SSTR3 and SSTR4 as well as deletion constructs and point mutants of SSTR3 has revealed that several serine residues and one threonine residue in the C-terminal intracellular domain of SSTR3 are required for internalization (13) . For the ␤ 2 -adrenergic receptor as well as receptors for thyrotropin-releasing hormone, gastrin-releasing peptide, and neurotensin, internalization has also been shown to rely on the presence of one or more hydroxyl amino acid residues in the C-terminal tails of the receptors (1, 16 -18) .
Here we show that mutation of each of the four mentioned serine and threonine residues in the C terminus of SSTR3 not only severely affects the rate and extent of receptor internalization but also coincides with a reduction in the agonist-dependent phosphorylation and desensitization of mutant receptors, suggesting that phosphorylation of these residues leads to desensitization and subsequent internalization.
MATERIALS AND METHODS
cDNA Constructs-Constructs of the rat SSTR3 containing a sequence encoding 11 amino acids of the T7 major capsid protein at the N terminus of the receptor sequence have been described previously (13) . All constructs were cloned into the cytomegalovirus promoter-based expression vector pcDNA3 (Invitrogen, Leeks, The Netherlands), which carries the neomycin resistance gene. Point mutants were constructed by PCR using two complementary mutagenic primers, as described by Higuchi (19) . The triple serine to alanine mutant was generated by * This work was supported in part by the Deutsche Forschungsgemeinschaft SFB232/B4 (to D. R. and W. M.) and Ri 192/20-1 (to D. R.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. (20) and selected in medium containing 450 g/ml G418 (Life Technologies, Inc.). The whole pool of G418-resistant cells was used without selection of individual cell clones.
Confocal Microscopy-For microscopic analysis, receptor-expressing cells were grown on glass coverslips treated with poly-D-lysine. After treatment with agonists and FITC-transferrin (Molecular Probes), transfected HEK cells were immediately fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS), pH 7.4, at room temperature for 3 min. Fixed cells were washed three times with PBS, permeabilized with ice-cold methanol, and washed again three times with PBS. To reduce nonspecific antibody binding, cells were preincubated with 2% goat serum at room temperature for 1 h. Monoclonal mouse anti-T7-tag antibody (Novagen, Madison, WI) was then added, and the cells were kept at room temperature for 3-4 h. Cells were washed (five times with PBS at room temperature for 10 min), and exposed to cy3-conjugated goat anti-mouse IgGs (Jackson ImmunoResearch Labs., Inc., West Grove, PA) at room temperature for 3 h. After washing (three times with PBS at room temperature for 10 min), cells were embedded in glycerol-gelatin (Sigma, Munich, Germany).
The cells were then examined using a confocal microscope (Zeiss Laser Scan Inverted 410 Axiovert microscope with an argon-krypton/ helium-neon laser) with fluorescein (line selection 488 nm, main dichroic mirror 488/543 nm, emission band pass 510 -525 or 515-565 nm) and cy3/rhodamine (line selection 543 nm, main dichroic mirror 488/543 nm, emission long pass 570 nm) filters. All images were processed using Adobe Photoshop on a Power MacIntosh 7600/120 computer, and printed on a Kodak photoprinter.
Radioligand Binding Assays-Assays for determining the number of binding sites on transfected HEK cells after agonist-dependent internalization were carried out as previously reported (13) . In brief, cells were incubated with 1 M SST14 at 37°C for the times indicated. Unbound ligand and ligand bound to cell surface receptors were removed using an acidic wash procedure (21) , and the number of remaining surface SST binding sites was determined by incubation with 100 pM [ 125
I-Tyr

11
]SST14 (specific activity, 2000 Ci/mmol, Amersham, Braunschweig, Germany) in growth medium on ice for 2 h, followed by four rapid washes with ice-cold PBS.
Membranes were prepared from transfected HEK cells (22) , and the binding characteristics of wild-type and mutant SSTR3 were determined by saturation binding assays. Determination of SSTR3 Desensitization by Measurement of cAMP Accumulation-For the measurement of cAMP accumulation, transfected cells were exposed to serum-free DMEM containing 500 M isobutyl methylxanthine for 30 min at 37°C. In desensitization experiments, SST14 was included in this incubation medium for the last 10 min. Medium was then replaced with the same medium containing forskolin (16 nM) with or without SST14 (10 nM). After incubation at 37°C for 10 min, the medium was removed, and the cells were extracted overnight with 300 l of 70% ethanol at Ϫ20°C. Extracts were lyophilized using a SpeedVac, and the cAMP contents were determined using a commercially available cAMP radioimmunoassay kit (DuPont NEN) which relies on the competition of cAMP for the binding of 125 I-labeled succinyl cAMP tyrosine methylester to a cAMP-specific antibody. The assay was performed according to the instructions of the manufacturer.
Agonist-dependent Phosphorylation-Transfected cells were plated into six-well dishes 2 days before the experiment. After incubation for 1 h in serum-free, phosphate-free DMEM, cells were loaded with 50 -100 Ci of [ 32 P]orthophosphate (285 Ci/mg phosphate; ICN, Costa Mesa, CA) per well for 1 h in the same medium at 37°C. SST14 was then added and incubation continued at 37°C. Cells were then washed three times with cold PBS and lyzed in radioimmune precipitation buffer (1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 5 mM EDTA, 10 mM NaF, 10 mM sodium pyrophosphate, 0.2 mM phenylmethylsulfonyl fluoride, 1 mg/ml pepstatin A, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0). After centrifugation at 15,800 ϫ g for 30 min, the lysate was precleared with protein A-Sepharose (Pharmacia) at room temperature for 2 h. 32 P-Labeled receptor protein was then immunoprecipitated using 10 g of anti-T7-tag antibody and 150 l of protein A-Sepharose. The precipitate was collected by centrifugation, washed five times with radioimmune precipitation buffer, and denatured with SDS sample buffer at 60°C for 10 min. After SDS-polyacrylamide gel electrophoresis, the phosphorylated receptor was visualized by autoradiography.
For the measurement of the stoichiometry of receptor phosphorylation, the receptor was detected by Western blotting using the T7 antibody as a primary antibody and alkaline phosphatase-labeled goat-anti mouse as the secondary antibody. The amount of immunoreactive material in each lane was quantified by densitometric analysis of the SSTR3-specific bands at 76 kDa using the NIH Image software (developed at the United States National Institutes of Health and available on the Internet at http://rsb.info.nih.gov./nih-image/). A standard curve for the amount of T7-immunoreactive material was generated by simultaneous Western blot analysis of various amounts of the T7-positive control extract, which contains the T7 major capsid protein and is supplied by the manufacturer of the T7 antibody (Novagen, Madison, WI).
The receptor-associated radioactivity was quantified on the Western blots using a PhosphorImager. Band intensities were plotted against a calibration curve obtained by spotting various amounts of 32 P on nitrocellulose.
The specific radioactivity of the cellular ATP pool was determined as described previously (23) . Briefly, cell lysates were subjected to high performance liquid chromatography (Applied Biosystems 130A) using an AX300 ion exchange column (Applied Biosystems). After sample injection and equilibration of the column in 20 mM Tris-HCl, pH 7.5, for 10 min, the ATP was eluted in the same buffer using a gradient from 0 to 500 mM NaCl in 45 min. The peak corresponding to ATP was collected, and its radioactivity content was determined by liquid scintillation counting. To determine the concentration of total cellular ATP, the peak height was plotted against a standard curve obtained by injecting various amounts of ATP. The specific activity of [␥-32 P]ATP was 50 cpm/pmol ATP, which corresponds well to previously published data (6, 23) .
RESULTS
Molecular Determinants for Receptor Internalization and
Desensitization-Treatment of HEK cells expressing SSTR3 with 1 M SST14 leads to a rapid reduction in the number of cell surface SST14 binding sites. By site-directed mutagenesis we have previously identified four hydroxyl amino acid residues in the receptor C terminus which are essential for internalization (12, 13 Table I ) has a significant effect on the rate and extent of receptor internalization when compared with the wild-type receptor (Fig. 1) . The S341A and S346A mutations still allowed some agonist-dependent loss of cell surface binding sites, while the S351A and T357A mutants showed little if any reduction over the entire time period (Fig. 1) . Also the triple mutant S341A/S346A/S351A containing all three serine to alanine substitutions showed no reduction in the number of cell surface binding sites (data not shown). None of the mutations analyzed interfered with either ligand binding or functional expression of the receptor in HEK 293 cells; both the T357A and the triple serine mutants showed similar expression levels and agonist binding affinities as the wild-type receptor (Table I) . We determined if prolonged treatment of SSTR3 expressing cells reduces the efficiency of coupling of this receptor to second-messenger systems. SSTR3 is coupled to the inhibition of adenylate cyclase via pertussis toxin sensitive G proteins (24) . At a concentration of 10 nM, SST14 reduced the forskolinstimulated accumulation of cAMP in SSTR3 expressing HEK cells by 62 Ϯ 5% (Table I) . To determine a functional desensitization of SSTR3, cells were preincubated with SST14 prior to coincubation of SST14 and forskolin. Desensitization was manifested by a reduction of the SST14 effect on cAMP levels seen in the absence of preincubation, i.e. by a relative increase in cAMP accumulation. Preincubation of cells expressing SSTR3 with increasing concentrations of the ligand reduced the SST14-mediated effect on cAMP levels. Maximum desensitization was observed at a preincubation concentration of 30 nM SST14 (Fig. 2A) . Concentrations of SST14 higher than 100 nM did not yield reproducible results, presumably because large amounts of agonist could not be properly washed out after the preincubation, and the residual SST14 raised the concentration of agonist used in the coincubation with forskolin.
The triple serine mutant did couple to the adenylate cyclase system with a similar efficiency as the wild-type receptor (Table I). However, in contrast to the wild-type SSTR3, the inhibition of adenylate cyclase could not be diminished by preincubation with up to 100 nM SST14. Thus, this mutant did not exhibit any sign of functional desensitization ( Fig. 2A) .
As functional desensitization and internalization of SSTR3 could both be blocked by mutating the three serine residues, removal of receptors from the cell surface could be one possible mechanism of desensitization. Therefore, we investigated if the two phenomena could be biochemically separated by comparing their concentration dependence. While desensitization appeared to reach a maximum at a concentration of 30 nM present during the 10-min preincubation step (see above), internalization required a 30 -60-min preincubation (see also Fig. 1 ) to attain maximum level and did not saturate even at a concentration of 1 M SST14 (Fig. 2B) . Thus, desensitization and internalization appear to be separate events that occur sequentially.
Agonist-dependent Phosphorylation of SSTR3-As hydroxyl amino acids appeared to be involved in the internalization process, we investigated if the receptor undergoes agonist-dependent phosphorylation as an initial step in endocytosis. For this purpose, receptor expressing cells were loaded with [ 32 P]orthophosphate, and the agonist-dependent receptor phosphorylation was determined by immunoprecipitation of receptors from cell lysates using an antibody directed against the T7 epitope tag, followed by SDS-gel electrophoresis. Fig. 3 shows that the wild-type SSTR3 exhibits a basal level of phosphorylation, and that this level is markedly increased by treatment with 1 M SST14. Analysis of the concentration dependence and time course of SSTR3 phosphorylation reveals that a significant increase in receptor phosphorylation is observed after treatment with 1 nM SST14 for 30 min; the effect reaches its maximum at a concentration of 100 nM SST14 and is slightly reduced at 1 M SST14 (Fig. 3A) . Increased phosphorylation can be observed after 5 min of agonist treatment and remains unaltered after 30 min of stimulation with 1 M SST14 (Fig. 3B) . After 60 min of treatment with agonist, however, we observed a decrease in the phosphorylation level that might be due to the internalization of the receptor into the endocytotic compartment and the subsequent action of receptor-specific phosphatases that have been shown to be present in the endocytotic compartment (25) .
Quantification of the receptor-associated radioactivity indi- cates that the basal level of receptor phosphorylation is 0.77 mol of phosphate per mol of receptor. This level is increased to 2.31 mol/mol by treatment with 1 M SST14 for 30 min (Fig. 4 , Table II) Comparison of the T357A and triple serine (S341A/S346A/ S351A) mutant receptors with the wild-type SSTR3 revealed that the T357A mutant exhibited a reduced level of basal phosphorylation (0.44 mol/mol), as well as a reduction in the increase of receptor-associated phosphate induced by 30 min of stimulation with 1 M SST14 (1.07 mol/mol). In the case of the triple mutant, little or no basal phosphorylation of the receptor could be detected, and the increase after agonist treatment was also very small (0.34 mol/mol, Fig. 4 
SSTR3 Is Internalized into the Same Intracellular Compartment as FITC-labeled
Transferrin-To define the endocytotic pathway used by SSTR3, we attempted to colocalize the receptor with FITC-labeled transferrin. This apoprotein is known to be endocytosed together with the transferrin receptor via clathrin-coated pits into endosomes (26) . Before treatment of HEK cells expressing SSTR3 with SST14, receptor-specific immunofluorescence was localized exclusively to the cell surface by confocal microscopy (Fig. 5A ). After treatment with SST14 and FITC-labeled transferrin, the tagged SSTR3 (Fig. 5B) and transferrin (Fig. 5C ) using red (cy3) and green (FITC) fluorescence, respectively, were both found in numerous intracellular vesicle-like structures. After merging the two pictures, the yellow-orange signal (Fig. 5D) indicates extensive colocalization of SSTR3 and transferrin in the same intracellular compartments.
Internalized SSTR3 Is Recycled to the Cell Surface-After internalization and subsequent washout of the agonist, fluorescence for SSTR3 returns to the cell surface of transfected HEK cells (Fig. 6A) . We investigated if this reappearance is due to de   FIG. 3 . Agonist-dependent phosphorylation of SSTR3. Wildtype SSTR3-expressing cells loaded with [ 32 P]orthophosphate were stimulated with SST14 using different concentrations (A) and times (B) as indicated, and receptors were immunoprecipitated as described under "Materials and Methods." After immunoprecipitation and electrophoresis, the intensities of the 78-kDa SSTR3-specific phosphorylated bands were quantified using a PhosphorImager.
FIG. 4. Phosphorylation of wild-type and mutant SSTR3. Cells loaded with [
32 P]orthophosphate were treated with or without 1 M SST14 for 30 min. The receptors were immunoprecipitated as described under "Materials and Methods," followed by SDS-gel electrophoresis. To ensure that equal amounts of receptor were loaded onto each lane, the number of cell surface binding sites was determined in a separate experiment by ligand binding, and the volume of the final eluate of the immunoprecipitation that was loaded on the gel was adjusted accordingly. The gel was electroblotted on a nitrocellulose membrane and probed with the T7 monoclonal antibody for the detection of precipitated SSTR3 (lower panel). Receptor-associated radioactivity novo synthesis of receptors or to recycling of the receptors from the endosomal compartment to the cell surface. Cycloheximide, an inhibitor of protein synthesis, did not prevent the reappearance of receptors at the cell surface. In contrast, brefeldin A, an inhibitor of the assembly of the Golgi apparatus, did prevent this process (Fig. 6A) . Our findings are supported by the biochemical measurement of cell surface receptors in these cells. These data show that SST14 binding sites start to reappear at the cell surface within 10 min of the removal of agonist. Again this process could not be blocked by cycloheximide (Fig. 6B) , suggesting that the SSTR3 is recycled after internalization.
DISCUSSION
Previous evidence from other GPCRs has suggested that the main route for internalization is via clathrin coated pits and vesicles into endosomes, a pathway which is also used by the transferrin receptor and its ligand. For the ␤ 2 -adrenergic receptor, phosphorylation of a cluster of hydroxyl amino acids in the C terminus of the protein is essential for desensitization and internalization (1) . The intracellular protein ␤-arrestin binds to the phosphorylated receptor and functions as an adaptor between the receptor and the clathrin molecules of clathrin coated pits (4). It is controversial whether all GPCRs are internalized in this way, and recently Zhang et al. (27) have provided evidence that an alternative pathway exists for the angiotensin II type 1a receptor. The colocalization of the internalized SSTR3 with FITC-labeled transferrin shown in this study provides evidence that SSTR3 is internalized into early endosomes via a clathrin-dependent pathway (26) . Endocytosis of SSTR3 can also be inhibited by phenylarsine oxide (13), a reagent which has been used as a specific inhibitor of clathrin-dependent endocytosis (5) . Thus, the question arose whether SSTR3, like the ␤ 2 -adrenergic receptor, undergoes phosphorylation at specific hydroxyl residues in the C terminus, which would facilitate binding of ␤-arrestin and subsequent targeting to the endocytotic machinery. Our mutational analysis of SSTR3 clearly shows that four hydroxyl amino acids in the receptor C terminus are necessary for internalization, suggesting that they are targets for agonist-dependent phosphorylation. An unexpected finding was that each individual serine and the threonine residue, when mutated to alanine, has a severe effect on the rate and extent of receptor internalization. It has become clear that most GPCRs can be phosphorylated at multiple intracellular residues (e.g. see Gurevich et al. (28) ), but in most cases it is unknown whether all of these residues are required for either desensitization or internalization.
Our in vitro phosphorylation experiments show that SSTR3 is indeed phosphorylated in an agonist-dependent manner. The receptor exhibits significant basal phosphorylation at a level of 0.77 mol of phosphate per mol receptor, and the extent of phosphorylation can be increased more than 2-3-fold by treatment with 1 M SST14. The T357A mutant shows a significant decrease in the basal as well as in the agonist-induced phosphorylation. This effect is even more pronounced in a triple mutant in which all three serine residues were replaced by alanines. Here basal phosporylation of the receptor becomes undetectable. Thus all four hydroxyl residues identified here contribute to the basal as well as to the agonist-induced phosphorylation of SSTR3. In our experiments we did not observe the "ideal" number of 4 mol of phosphate per mol of receptor, but this may be expected as only 60 -70% of the receptors are internalized after treatment with agonist for 30 min (Fig. 1) . The other cell surface receptors may not be functionally coupled to G proteins and thus not be available as a substrate for receptor kinases. It should also be noted that the extent of the agonist induced phosphorylation of the wild-type receptor is probably underestimated in these experiments, because the population of internalized receptors is exposed to Ser/Thr-phosphatases which are present in endosomal fractions of the cell (25) and which have been implicated in the resensitization of GPCRs after desensitization/internalization (6, 25) . This is particularly evident in our experiments when long incubation times and/or high concentrations of agonist were used; this led to more extensive internalization of the receptor. The observed increase in SSTR3 phosphorylation was slightly reduced in these cases.
Taken together, our data are compatible with a model in which all four residues need to be phosphorylated to induce internalization. One or more of these residues may be phosporylated in the resting state, but this is not sufficient to induce desensitization and internalization.
Second-messenger activated kinases have been implicated in the desensitization of G protein-coupled receptors. Out of the four hydroxyl amino acid residues identified here, only Ser 346 fits the consensus sequence of the multifunctional calmodulindependent protein kinase II. Therefore it is likely that phosphorylation of the SSTR3 C terminus is brought about by one of the GPCR-specific kinases, which recognizes a rather broad spectrum of sequences (29) . Earlier work has shown that stimulation of S49 cells with somatostatin leads to translocation of a GPCR-specific kinase to the membrane (30) .
When assayed for its ability to inhibit adenylate cyclase, SSTR3 functionally desensitizes even after treatment with low concentrations of agonists. In contrast, the triple mutant receptor, while fully functional in this assay, shows no sign of desensitization even when preincubated with SST14 at concentrations of up to 100 nM. As mutation of these residues affects desensitization and internalization, one might speculate that removal of receptors from the cell surface is the actual mechanism of functional desensitization. However, this is not the case, as the concentration dependence of the two processes is different. It has previously been shown for other GPCRs that desensitization and internalization can be biochemically separated (6, 31) . Our data suggest that SSTR phosphorylation at the four hydroxyl amino acids leads to uncoupling of the receptor from G proteins. This functional desensitization precedes endocytosis of the receptor. As endocytosis involves the same intracellular pathway used by the ␤ 2 -adrenergic receptor, it appears likely that this process is brought about by the binding of ␤-arrestin to the phosphorylated receptor. However, it remains to be shown whether the isoforms of ␤-arrestin can actually bind to SSTR3 or whether other adaptors exist which can target GPCRs to the endocytotic pathway.
For the ␤ 2 -adrenergic receptor it has been shown that endocytosis is necessary for the resensitization of the receptor after functional desensitization (6) . Our experiments indicate that SSTR3 is regulated similarly, as it efficiently recycles to the cell surface after internalization and subsequent removal of the agonist. Phosphate groups are removed from the receptor C terminus in an endosomal compartment, as observed here under conditions of extensive internalization (see above), and the acidic environment of the endosome favors dissociation of SST14 from its receptor (21) . Thus the receptor returns to the cell surface in a functional state.
